Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Elucidating the cause of multiple system atrophy in a Korean cohort
FY 2014-15
Summary
Multiple system atrophy (MSA) is a rare disorder that is similar to Parkinson's disease (PD). While similar clinically to PD, MSA progresses much faster than PD. Also, many MSA patients are poorly responsive to L-DOPA, a typical drug given to PD patients. Furthermore, the genetic cause of MSA has yet to be identified.
Through collaboration with a Korean neurologist, my lab (the Farrer lab) has received ~300 MSA DNA samples. To identify the genetic basis of MSA, I will sequence protein-coding regions of the genomes of 50 of the most severe cases of MSA as well as 25 Korean controls to reveal all mutations found in these regions. Next, I will narrow down potential causative mutations by filtering through all mutations and identifying only those that change the protein sequence and that are computationally predicted to be damaging to the protein. Hopefully after this point, there are only one or two potential mutations. In a similar fashion, I will use a different technique to detect mutations in the 50 MSA cases and 25 controls and the results will be compared with the sequencing data. I will validate rare mutations in common between the two techniques that are predicted to be damaging and analyze them in a broader Korean cohort. I expect any mutation likely to cause MSA to appear at a very low frequency in the Korean cohort as MSA is a rare disease. Finally, I will conduct experiments to verify that the potential mutation is capable of causing disease.
The outcome of this project has potential clinical implications. By identifying a disease-causing gene, the disrupted biochemical pathway can be further understood to determine how MSA is caused. In addition, the identification of a disease-causing gene may lead to this gene becoming a potential drug target for MSA.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331521
Name
Scott Erika
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the cause of multiple system atrophy in a Korean cohort
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Multiple System Atrophy; Neurodegeneration; Rare Disease; Sanger Sequencing; Snp Genotyping; Whole-Exome Sequencing
Abstract
Multiple system atrophy (MSA) is a rare disorder that is similar to Parkinson's disease (PD). While similar clinically to PD, MSA progresses much faster than PD. Also, many MSA patients are poorly responsive to L-DOPA, a typical drug given to PD patients. Furthermore, the genetic cause of MSA has yet to be identified.
Through collaboration with a Korean neurologist, my lab (the Farrer lab) has received ~300 MSA DNA samples. To identify the genetic basis of MSA, I will sequence protein-coding regions of the genomes of 50 of the most severe cases of MSA as well as 25 Korean controls to reveal all mutations found in these regions. Next, I will narrow down potential causative mutations by filtering through all mutations and identifying only those that change the protein sequence and that are computationally predicted to be damaging to the protein. Hopefully after this point, there are only one or two potential mutations. In a similar fashion, I will use a different technique to detect mutations in the 50 MSA cases and 25 controls and the results will be compared with the sequencing data. I will validate rare mutations in common between the two techniques that are predicted to be damaging and analyze them in a broader Korean cohort. I expect any mutation likely to cause MSA to appear at a very low frequency in the Korean cohort as MSA is a rare disease. Finally, I will conduct experiments to verify that the potential mutation is capable of causing disease.
The outcome of this project has potential clinical implications. By identifying a disease-causing gene, the disrupted biochemical pathway can be further understood to determine how MSA is caused. In addition, the identification of a disease-causing gene may lead to this gene becoming a potential drug target for MSA.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Scott, Erika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~